HONORHEALTH DEER VALLEY MED CTR
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $1.4M
- Transactions
- 412
- Companies
- 23
- Average per transaction
- $3,374
Who reported the payments
| Cardiofocus, Inc. | $300,000 |
| Regeneron | $202,639 |
| Springworks Therapeutics, Inc. | $148,076 |
| Galvanize Therapeutics, Inc | $106,468 |
| Deciphera Pharmaceuticals Inc. | $105,995 |
| Pfizer | $93,414 |
| Takeda Pharmaceuticals U.S.A., Inc. | $79,957 |
| Morphosys AG | $57,125 |
| Krystal Biotech Inc | $48,255 |
| Bolton Medical Inc | $40,000 |
| Novartis | $32,849 |
| Stryker | $30,609 |
| Boston Scientific | $29,085 |
| Bard Peripheral Vascular, Inc. | $24,695 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $23,543 |
| Gynesonics, Inc. | $20,645 |
| UCB SA | $18,451 |
| AbbVie | $17,020 |
| Shockwave Medical, Inc | $5,001 |
| Olympus America Inc. | $3,729 |
| Applied Medical Technology Inc | $2,537 |
| Johnson & Johnson | $81 |
| BD | $50 |